Douglas E. Murphy

909 citations

24 papers · 817 · h-index 16

Impact in

Hepatology top 5%
- Hepatitis C virus research
Organic Chemistry top 5%
- Multicomponent Synthesis of Heterocycles
- Synthesis and biological activity
- Synthesis of heterocyclic compounds

Papers in

Hepatology 11
- Hepatitis C virus research 11
Organic Chemistry 10
- Synthesis of heterocyclic compounds 3
- Synthesis and biological activity 2
- Synthesis and Biological Evaluation 1

Co-authors: Yuefen Zhou (12 shared papers)Zhongxiang Sun (9 shared papers)Vlad E. Gregor (4 shared papers)Benjamin K. Ayida (5 shared papers)Thomas Hermann (5 shared papers)Stephen E. Webber (6 shared papers)Jamie M. Froelich (3 shared papers)Daniel B. Wall (3 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (12 papers)Journal of Medicinal Chemistry (3 papers)Tetrahedron Letters (2 papers)Synthesis (2 papers)Antiviral Research (1 paper)
Partner nations: United States Denmark

In The Last Decade

Douglas E. Murphy

24 papers receiving 699 citations

Peers

Countries citing papers authored by Douglas E. Murphy

Since Specialization

Citations

This map shows the geographic impact of Douglas E. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas E. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas E. Murphy more than expected).

Fields of papers citing papers by Douglas E. Murphy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas E. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas E. Murphy. The network helps show where Douglas E. Murphy may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas E. Murphy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas E. Murphy Line = papers co-authored together Douglas E. Murphy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition Journal of Medicinal Chemistry ·Siegfried Reich, Paul A. Sprengeler, Gary Gene Chiang, James Richard Appleman, Joan W. Chen, Jeffrey Clarine, Boreth Eam, Justin T. Ernst	2018	153
2	Synthesis and SAR of 3,5-diamino-piperidine derivatives: Novel antibacterial translation inhibitors as aminoglycoside mimetics Bioorganic & Medicinal Chemistry Letters ·Yuefen Zhou, Vlad E. Gregor, Benjamin K. Ayida, Geoffrey C. Winters, Zhongxiang Sun, Douglas E. Murphy, Gregory Haley, Jamie M. Froelich	2006	117
3	Optimization of Alkylidene Hydrazide Based Human Glucagon Receptor Antagonists. Discovery of the Highly Potent and Orally Available 3-Cyano-4-hydroxybenzoic Acid [1-(2,3,5,6-Tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide Journal of Medicinal Chemistry ·Peter Madsen, Anthony L Ling, Michael B. Plewe, Christian K. Sams, Lotte Bjerre Knudsen, Ulla Grove Sidelmann, Lars Ynddal, Christian Lehn Brand	2002	82
4	Structure-Guided Discovery of Novel Aminoglycoside Mimetics as Antibacterial Translation Inhibitors Antimicrobial Agents and Chemotherapy ·Yuefen Zhou, Vlad E. Gregor, Zhongxiang Sun, Benjamin K. Ayida, Geoffrey C. Winters, Douglas E. Murphy, Klaus Baek Simonsen, Dionisios Vourloumis	2005	43
5	Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists Journal of Medicinal Chemistry ·Anthony L Ling, Yufeng Hong, Javier González, Vlad E. Gregor, Alex Polinsky, Atsuo Kuki, Shenghua Shi, Kimberly Teston	2001	41
6	Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Frank Ruebsam, Douglas E. Murphy, Chinh V. Tran, Lian‐Sheng Li, Jingjing Zhao, Peter S. Dragovich, Alan X. Xiang, Zhongxiang Sun	2009	41
7	Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: Exploration of 7′-substitution of benzothiadiazine Bioorganic & Medicinal Chemistry Letters ·Yuefen Zhou, Stephen E. Webber, Douglas E. Murphy, Lian‐Sheng Li, Peter S. Dragovich, Chinh V. Tran, Zhongxiang Sun, Frank Ruebsam	2008	38
8	Novel parallel synthesis of N-(4-oxo-2-substituted-4H-quinazolin-3-yl)-substituted sulfonamides Tetrahedron Letters ·Yuefen Zhou, Douglas E. Murphy, Zhongxiang Sun, Vlad E. Gregor	2004	36
9	Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Frank Ruebsam, Stephen E. Webber, Martin T. Tran, Chinh V. Tran, Douglas E. Murphy, Jingjing Zhao, Peter S. Dragovich, Sun Hee Kim	2008	36
10	Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments Bioorganic & Medicinal Chemistry Letters ·Lian‐Sheng Li, Yuefen Zhou, Douglas E. Murphy, Nebojsa S. Stankovic, Jingjing Zhao, Peter S. Dragovich, Thomas M. Bertolini, Zhongxiang Sun	2008	31
11	Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents Bioorganic & Medicinal Chemistry Letters ·Yuefen Zhou, Lian‐Sheng Li, Peter S. Dragovich, Douglas E. Murphy, Chinh V. Tran, Frank Ruebsam, Stephen E. Webber, Amit M. Shah	2008	28
12	Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Sun Hee Kim, Martin T. Tran, Frank Ruebsam, Alan X. Xiang, Benjamin K. Ayida, Julie K. Blazel, Chinh V. Tran, Douglas E. Murphy	2008	28
13	5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Frank Ruebsam, Chinh V. Tran, Lian‐Sheng Li, Sun Hee Kim, Alan X. Xiang, Yuefen Zhou, Julie K. Blazel, Zhongxiang Sun	2008	25
14	Efficient synthesis of 2,6-disubstituted-5-hydroxy-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid ethyl esters Tetrahedron Letters ·Douglas E. Murphy, Peter S. Dragovich, Benjamin K. Ayida, Thomas M. Bertolini, Lian‐Sheng Li, Frank Ruebsam, Nebojsa S. Stankovic, Zhongxiang Sun	2007	22
15	Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents Bioorganic & Medicinal Chemistry Letters ·Peter S. Dragovich, Julie K. Blazel, David A. Ellis, Qing Han, Ruhi Kamran, Charles R. Kissinger, Laurie A. LeBrun, Lian‐Sheng Li	2008	22
16	Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties Bioorganic & Medicinal Chemistry Letters ·Maria V. Sergeeva, Yuefen Zhou, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Ellen Okamoto, Leo Kirkovsky, Ruhi Kamran	2008	20
17	Regiospecific synthesis of 1,5-disubstituted-1H-pyrazoles containing differentiated 3,4-dicarboxylic acid esters via Suzuki coupling of the corresponding 5-trifluoromethane sulfonates Tetrahedron ·Peter S. Dragovich, Thomas M. Bertolini, Benjamin K. Ayida, Lian‐Sheng Li, Douglas E. Murphy, Frank Ruebsam, Zhongxiang Sun, Yuefen Zhou	2006	16
18	Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors Bioorganic & Medicinal Chemistry Letters ·Yuefen Zhou, Douglas E. Murphy, Zhongxiang Sun, Thomas M. Bertolini, Jamie M. Froelich, Stephen E. Webber, Thomas Hermann, Daniel B. Wall +1 other	2008	11
19	5,5′- and 6,6′-Dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Julie K. Blazel, Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Lian‐Sheng Li, Jingjing Zhao, Yuefen Zhou, Alan X. Xiang	2009	11
20	Efficient synthesis of (1R,2S) and (1S,2R)-2-aminocyclopentanecarboxylic acid ethyl ester derivatives in enantiomerically pure form Tetrahedron Asymmetry ·Peter S. Dragovich, Douglas E. Murphy, Kimkim Dao, Sun Hee Kim, Lian‐Sheng Li, Frank Ruebsam, Zhongxiang Sun, Chinh V. Tran	2008	6

About Douglas E. Murphy

Douglas E. Murphy is a scholar working on Hepatology, Organic Chemistry, Molecular Biology, Endocrinology, Diabetes and Metabolism and Pharmacology, having authored 24 papers that have together received 817 indexed citations. Recurring topics across this work include Hepatitis C virus research (11 papers), RNA and protein synthesis mechanisms (4 papers), Synthesis of heterocyclic compounds (3 papers), Phenothiazines and Benzothiazines Synthesis and Activities (2 papers), Synthesis and biological activity (2 papers), Diabetes Treatment and Management (2 papers), Synthesis and Biological Evaluation (1 paper) and Microbial Natural Products and Biosynthesis (1 paper). The work is most often cited by research in Hepatology (136 citations), Organic Chemistry (322 citations), Computational Theory and Mathematics (114 citations), Endocrinology, Diabetes and Metabolism (58 citations) and Molecular Biology (170 citations). Douglas E. Murphy has collaborated with scholars based in United States and Denmark. Frequent co-authors include Yuefen Zhou, Zhongxiang Sun, Vlad E. Gregor, Benjamin K. Ayida, Thomas Hermann, Stephen E. Webber, Jamie M. Froelich, Daniel B. Wall, Sarah Fish and Geoffrey C. Winters. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Tetrahedron Letters, Synthesis and Antiviral Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Douglas E. Murphy

Impact in

Papers in i

In The Last Decade

Douglas E. Murphy

Peers

Countries citing papers authored by Douglas E. Murphy

Fields of papers citing papers by Douglas E. Murphy

All Works

About Douglas E. Murphy

Explore authors with similar magnitude of impact

Papers in